1.05
-23.36%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orexo
Its shares trade on Nasdaq Stockholm under the ticker ORX.ST. It has been listed since 9 November 2005. In the fiscal year to 31 December 2025, it reported revenue of SEK 26.0m and a net loss of SEK 129.8m. At that date it held total assets of SEK 1.30bn and shareholders' equity of SEK 490.6m.
Orexo AB is engaged in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Nov 2005
- Employees
- 132
- Website
- orexo.com ↗
Leadership
Pay as last reported
- Dr. Friedrich von Bohlen Und HalbachIndependent Chairman of the BoardSEK 53,000
- Mr. Nikolaj SorensenPresident, Chief Executive OfficerSEK 7.5m
- Mr. Fredrik JaerrstenChief Financial Officer, Executive Vice President
- Mr. Robert DelucaPresident of Orexo US Inc
- Ms. Cecilia CouplandSenior Vice President, Head - Operations
- Mr. Robert RoennSenior Vice President, Head - Research and Development
- Mr. Edward KimChief Medical Officer
- Mr. Robin EversIndependent DirectorSEK 450,000
- Mr. Staffan LindstrandIndependent DirectorSEK 550,000
- Ms. Christine RankinIndependent DirectorSEK 600,000
- Mr. Fred WilkinsonIndependent DirectorSEK 400,000
- Ms. Lena WangeInvestor Relations and Communications Director, since 2015
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 79
- Social
- 93
- Governance
- 76
- Direct emissions (scope 1)
- 273 t
- Energy emissions (scope 2)
- 73 t
- Value chain emissions (scope 3)
- 1,314 t
- Women in the workforce
- 54%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market position: Orexo AB holds a significant position in the pharmaceutical industry, particularly in the field of medication for the treatment of opioid dependence.
- Innovative product portfolio: The company offers unique and innovative pharmaceutical products, such as Zubsolv, which have demonstrated effectiveness and are well-received by the market.
- Strong research and development capabilities: Orexo AB invests heavily in R&D to develop new medications and enhance existing products. This enables the company to stay at the forefront of technological advancements in the industry.
Weaknesses
- Limited product diversification: Orexo AB heavily relies on a few key products, making it vulnerable to changes in market demand or competition in those specific therapeutic areas.
- Geographic concentration: The company's revenue is mainly derived from markets in the United States and Europe, leading to potential risks associated with regional economic fluctuations or regulatory changes.
- Patent expiration: Some of Orexo AB's major products will face patent expiration in the near future, exposing the company to potential competitors and generic alternatives.
Opportunities
- Expansion into emerging markets: Orexo AB can explore growth opportunities in emerging markets where the demand for opioid dependence treatment and other pharmaceuticals is increasing.
- Collaborations and strategic partnerships: The company can develop partnerships with other pharmaceutical companies to access new technologies, diversify its product portfolio, and expand its market reach.
- Increasing focus on mental health: With the growing importance of mental health awareness, Orexo AB can develop and market medications targeting mental health disorders to address this expanding market segment.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, and Orexo AB faces competition from both large multinational corporations and smaller specialized companies.
- Stringent regulatory requirements: The industry is subject to strict regulations and compliance standards, which may impose additional costs and delays on product development and commercialization.
- Market volatility and economic uncertainty: Economic instability, changes in healthcare policies, or unexpected events can adversely impact the demand for pharmaceutical products and the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.